Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy

Abstract

Cancer drug resistance constitutes a severe limitation for the satisfactory outcome of these patients. This is a complex problem due to the co-existence in cancer cells of multiple and synergistic mechanisms of chemoresistance (MOC). These mechanisms are accounted for by the expression of a set of genes included in the so-called resistome, whose effectiveness often leads to a lack of response to pharmacological treatment. Additionally, genetic variants affecting these genes further increase the complexity of the question. This review focuses on a set of genes encoding members of the transportome involved in drug uptake, which have been classified into the MOC-1A subgroup of the resistome. These proteins belong to the solute carrier (SLC) superfamily. More precisely, we have considered here several members of families SLC2, SLC7, SLC19, SLC22, SLCO, SLC28, SLC29, SLC31, SLC46, and SLC47 due to the impact of their expression and genetic variants in anticancer drug uptake by tumor cells or, in some cases, general bioavailability. Changes in their expression levels and the appearance of genetic variants can contribute to the Darwinian selection of more resistant clones and, hence, to the development of a more malignant phenotype. Accordingly, to address this issue in future personalized medicine, it is necessary to characterize both changes in resistome genes that can affect their function. It is also essential to consider the time-dependent dimension of these features, as the genetic expression and the appearance of genetic variants can change during tumor progression and in response to treatment.

Keywords

Cancer / chemotherapy / pharmacogenetics / single nucleotide alteration / single nucleotide polymorphism / transportome

References

[1] Marin JJ,Blazquez AG,Serrano MA.The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.Acta Pharmacol Sin2014;35:1-10 PMCID:PMC3880477

[2] Marin JJG,Monte MJ.Molecular bases of drug resistance in hepatocellular carcinoma.Cancers2020;12:1663 PMCID:PMC7352164

[3] Marin JJG,Herraez E.Mechanisms of pharmacoresistance in hepatocellular carcinoma: new drugs but old problems.Semin Liver Dis2022;42:87-103

[4] Schaller L.The genetic landscape of the human solute carrier (SLC) transporter superfamily.Hum Genet2019;138:1359-77 PMCID:PMC6874521

[5] Al-Abdulla R,Abete L,Briz O.Unraveling “The Cancer Genome Atlas” information on the role of SLC transporters in anticancer drug uptake.Expert Rev Clin Pharmacol2019;12:329-41

[6] Huang KM,DiGiacomo D,Hu S.Role of SLC transporters in toxicity induced by anticancer drugs.Expert Opin Drug Metab Toxicol2020;16:493-506 PMCID:PMC7512084

[7] Baldwin SA,Yao SY,Cass CE.The equilibrative nucleoside transporter family, SLC29.Pflugers Arch2004;447:735-43

[8] Mata JF,Lostao MP.Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.Mol Pharmacol2001;59:1542-8

[9] Álvarez-Arenas A,Belmonte-Beitia J,Calvo GF.Interplay of darwinian selection, lamarckian induction and microvesicle transfer on drug resistance in cancer.Sci Rep2019;9:9332 PMCID:PMC6597577

[10] Hagenbuch B.The SLCO (former SLC21) superfamily of transporters.Mol Aspects Med2013;34:396-412 PMCID:PMC3602805

[11] Hagenbuch B.Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties.Pflugers Arch2004;447:653-65

[12] Schulte RR.Organic anion transporting polypeptides: emerging roles in cancer pharmacology.Mol Pharmacol2019;95:490-506 PMCID:PMC6442320

[13] Lee W,Smith LH.Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.J Biol Chem2005;280:9610-7

[14] Badagnani I,Taylor TR.Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.J Pharmacol Exp Ther2006;318:521-9

[15] Hu S,Filipski KK.Interaction of imatinib with human organic ion carriers.Clin Cancer Res2008;14:3141-8

[16] Yamakawa Y,Shuto T.Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.Clin Pharmacol Ther2011;90:157-63

[17] Cheng Y,Zhuang Q.Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.Pediatr Blood Cancer2021;68:e28858

[18] Wang SM,Wu WS,Yan D.Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.Leuk Res2018;65:61-6

[19] Huang L,Xie C.SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.PLoS One2013;8:e77223 PMCID:PMC3797132

[20] Radtke S,Renner B.Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.Blood2013;121:5145-53

[21] Bins S,El Bouazzaoui S.Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Pharmacogenomics2016;17:1483-90

[22] Reimer T,Gerber B,Hartmann S.SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.BMC Cancer2016;16:337 PMCID:PMC4884353

[23] Eldem İ,Cumaoğullari Ö.SLCO1B1 polymorphisms are associated with drug intolerance in childhood leukemia maintenance therapy.J Pediatr Hematol Oncol2018;40:e289-94

[24] Liu SG,Zhang RD.Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.Oncotarget2017;8:37761-72 PMCID:PMC5514947

[25] Han JY,Park YH,Lee JS.Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.Lung Cancer2009;63:115-20

[26] Park HS,Shin HJ.Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.Pharmacogenet Genomics2016;26:116-25

[27] Kloth JSL,Swen JJ.Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.Pharmacogenomics J2018;18:49-55

[28] Chew SC,Singh O.Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.Br J Clin Pharmacol2012;73:606-18 PMCID:PMC3376437

[29] Zhou F,Zhu L.Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2.AAPS J2013;15:1099-108 PMCID:PMC3787238

[30] Zamek-Gliszczynski MJ, Taub ME, Chothe PP, et al; International Transporter Consortium. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance.Clin Pharmacol Ther2018;104:890-9 PMCID:PMC8211378

[31] Kullak-Ublick GA,Stieger B.Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.Gastroenterology2001;120:525-33

[32] Nagai M,Matsumoto S.Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells.Biochem Biophys Res Commun2012;418:818-23

[33] Alam K,Ding K.Characterization of liver- and cancer-type-organic anion transporting polypeptide (OATP) 1B3 messenger RNA expression in normal and cancerous human tissues.Drug Metab Lett2018;12:24-32 PMCID:PMC6133766

[34] Al-Abdulla R,Lozano E.Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters.Biochem Pharmacol2020;171:113682

[35] van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice.Clin Cancer Res2013;19:821-32

[36] Asensio M,Macias RIR.Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma.Biochem Pharmacol2023;214:115681

[37] Garrison DA,Eisenmann ED,Baker SD.Role of OATP1B1 and OATP1B3 in drug-drug interactions mediated by tyrosine kinase inhibitors.Pharmaceutics2020;12:856 PMCID:PMC7559291

[38] Zimmerman EI,Roberts JL.Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.Clin Cancer Res2013;19:1458-66 PMCID:PMC3602278

[39] Ohya H,Ogura J,Kobayashi M.Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2.Biol Pharm Bull2015;38:582-6

[40] Picard N,Lamoureux F,Giacomini KM.Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters.Xenobiotica2011;41:752-7

[41] Boivin AA,Barama A.Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients.Drug Metab Pharmacokinet2013;28:274-7

[42] Gridelli C,Rossi A.The potential role of mTOR inhibitors in non-small cell lung cancer.Oncologist2008;13:139-47

[43] Zagouri F,Chrysikos D,Bartsch R.mTOR inhibitors in breast cancer: a systematic review.Gynecol Oncol2012;127:662-72

[44] Szklener K,Wieteska M,Bilski M.New directions in the therapy of glioblastoma.Cancers2022;14:5377 PMCID:PMC9655599

[45] Lee HH.Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).Br J Clin Pharmacol2017;83:1176-84 PMCID:PMC5427225

[46] Crowe A,Miller J.Characterization of plasma membrane localization and phosphorylation status of organic anion transporting polypeptide (OATP) 1B1 c.521 T>C nonsynonymous single-nucleotide polymorphism.Pharm Res2019;36:101 PMCID:PMC8456979

[47] SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study.N Engl J Med2008;359:789-99

[48] Marin JJG,Monte MJ.Role of genetic variations in the hepatic handling of drugs.Int J Mol Sci2020;21:2884 PMCID:PMC7215464

[49] Ramsey LB,Lee SB.PharmVar GeneFocus: SLCO1B1.Clin Pharmacol Ther2023;113:782-93 PMCID:PMC10900141

[50] Letschert K,König J.Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).Pharmacogenetics2004;14:441-52

[51] Lévi F,Saffroy R.Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).Br J Cancer2017;117:965-73 PMCID:PMC5625679

[52] Yu J,Tay-Sontheimer J,Ragueneau-Majlessi I.Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings.J Pharm Sci2017;106:2312-25

[53] Prasad B,Vrana M.Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics.Clin Pharmacol Ther2016;100:362-70 PMCID:PMC5017908

[54] Niemi M.Role of OATP transporters in the disposition of drugs.Pharmacogenomics2007;8:787-802

[55] Visentin M,Romero MF,Goldman ID.Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1).Mol Pharmacol2012;81:134-42 PMCID:PMC3263956

[56] Fujita D,Nakanishi T.Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38, active metabolite of irinotecan hydrochloride.Drug Metab Dispos2016;44:1-7

[57] Johnston RA,Chan T,Murray M.Selective inhibition of human solute carrier transporters by multikinase inhibitors.Drug Metab Dispos2014;42:1851-7

[58] Medwid S,Taylor DP.Organic anion transporting polypeptide 2B1 (OATP2B1) genetic variants: in vitro functional characterization and association with circulating concentrations of endogenous substrates.Front Pharmacol2021;12:713567 PMCID:PMC8476882

[59] Lee HH,Teft W,Kim RB.Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.Mol Cancer Ther2015;14:994-1003 PMCID:PMC4394048

[60] Buxhofer-Ausch V,Wlcek K.Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.J Drug Deliv2013;2013:863539 PMCID:PMC3574750

[61] Olszewski-Hamilton U,Thalhammer T,Geissler K.Organic anion transporting polypeptide 5A1 (OATP5A1) in small cell lung cancer (SCLC) cells: possible involvement in chemoresistance to satraplatin.Biomark Cancer2011;3:31-40 PMCID:PMC3791916

[62] Nigam SK.The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease.Annu Rev Pharmacol Toxicol2018;58:663-87 PMCID:PMC6225997

[63] Alexander SP,Mathie A.The concise guide to pharmacology 2021/22: transporters.Br J Pharmacol2021;178:S412-513

[64] Lozano E,Macias RIR,Marin JJG.Genetic heterogeneity of SLC22 family of transporters in drug disposition.J Pers Med2018;8:14 PMCID:PMC6023491

[65] Zhu C,Date RC.Evolutionary analysis and classification of OATs, OCTs, OCTNs, and other SLC22 transporters: structure-function implications and analysis of sequence motifs.PLoS One2015;10:e0140569 PMCID:PMC4633038

[66] Koepsell H.The SLC22 drug transporter family.Pflugers Arch2004;447:666-76

[67] Koepsell H.Role of organic cation transporters in drug-drug interaction.Expert Opin Drug Metab Toxicol2015;11:1619-33

[68] Lozano E,Briz O.Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.Biomed Res Int2013;2013:692071 PMCID:PMC3747481

[69] Di Paolo A,Capecchi M.The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.Pharmacogenomics J2014;14:328-35

[70] Qiu HB,Wu T.Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.Pharmacogenomics J2018;18:460-6

[71] Cargnin S,Soverini S,Terrazzino S.Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.Pharmacol Res2018;131:244-54

[72] Singh O,Lin K,Chowbay B.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.PLoS One2012;7:e51771 PMCID:PMC3525665

[73] Ravegnini G,Simeon V.An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor.Pharmacogenomics J2019;19:390-400

[74] Angelini S,Ravegnini G.Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Haematologica2013;98:193-200 PMCID:PMC3561425

[75] Angelini S,Ravegnini G.Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.Pharmacol Res2013;68:1-6

[76] Seitz T,Dalila N.Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.Genome Med2015;7:56 PMCID:PMC4495841

[77] Thomas J,Clark RE.Active transport of imatinib into and out of cells: implications for drug resistance.Blood2004;104:3739-45

[78] Minematsu T.Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.Mol Cancer Ther2011;10:531-9 PMCID:PMC3063525

[79] Wang L,Lane S,Pirmohamed M.Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.Clin Pharmacol Ther2008;83:258-64

[80] Nardinelli L,Didone A.Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.Acta Haematol2012;127:228-34

[81] Makhtar SM,Baba AA.Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients.J Genet2018;97:835-42

[82] Koren-Michowitz M,Ribakovsky E.OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.Eur J Haematol2014;92:283-8

[83] Herraez E,Macias RI.Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.Hepatology2013;58:1065-73

[84] Geier A,Bettinger D.The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.Oncotarget2017;8:15846-57 PMCID:PMC5362528

[85] Zhang S,Shima JE.Organic cation transporters are determinants of oxaliplatin cytotoxicity.Cancer Res2006;66:8847-57 PMCID:PMC2775093

[86] Pérez-Gómez N,Elizari-Roncal M.Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.Pharmacogenomics2023;24:651-63

[87] Koepsell H.Organic cation transporters in health and disease.Pharmacol Rev2020;72:253-319

[88] Fukushima-Uesaka H,Ozawa S.Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2).Drug Metab Pharmacokinet2004;19:239-44

[89] Visentin M,Gai Z.Fluorocholine transport mediated by the organic cation transporter 2 (OCT2, SLC22A2): implication for imaging of kidney tumors.Drug Metab Dispos2018;46:1129-36

[90] Ciarimboli G,Vollenbröcker B.New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2.Mol Pharm2011;8:270-9

[91] Nies AT,Schwab M.Hepatic solute carrier transporters and drug therapy: regulation of expression and impact of genetic variation.Pharmacol Ther2022;238:108268

[92] Chen L,Chen EC.Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3.Pharmacogenomics J2013;13:110-20 PMCID:PMC3396779

[93] Gründemann D,Golz S.Discovery of the ergothioneine transporter.Proc Natl Acad Sci U S A2005;102:5256-61 PMCID:PMC555966

[94] Okabe M,Reimers MA.Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.Mol Cancer Ther2008;7:3081-91 PMCID:PMC2597359

[95] Jong NN,Liu JJ,McKeage MJ.Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.J Pharmacol Exp Ther2011;338:537-47

[96] Drenberg CD,Pounds SB.OCTN1 is a high-affinity carrier of nucleoside analogues.Cancer Res2017;77:2102-11 PMCID:PMC5419029

[97] Hu C,Zuo Z.Inhibition of OCTN2-mediated transport of carnitine by etoposide.Mol Cancer Ther2012;11:921-9 PMCID:PMC3466062

[98] Li Q.Role of solute carriers in response to anticancer drugs.Mol Cell Ther2014;2:15 PMCID:PMC4452062

[99] Koepsell H.The SLC22 family with transporters of organic cations, anions and zwitterions.Mol Aspects Med2013;34:413-35

[100] Nigam SK.OAT, OATP, and MRP drug transporters and the remote sensing and signaling theory.Annu Rev Pharmacol Toxicol2023;63:637-60

[101] Uwai Y,Motohashi H,Okuda M.Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3.Drug Metab Pharmacokinet2004;19:369-74

[102] Sun W,van Poelje PD.Isolation of a family of organic anion transporters from human liver and kidney.Biochem Biophys Res Commun2001;283:417-22

[103] Marada VV,Kühne A,Burckhardt G.Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs.Pharmacol Res2015;91:78-87

[104] Hagos Y,Kuehne A.HNF4α induced chemosensitivity to oxaliplatin and 5-FU mediated by OCT1 and CNT3 in renal cell carcinoma.J Pharm Sci2014;103:3326-34

[105] Tashiro A,Takeda R.High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy.Am J Cancer Res2014;4:528-36 PMCID:PMC4163617

[106] Shin HJ,Lee SS,Shin JG.Identification of genetic polymorphisms of human OAT1 and OAT2 genes and their relationship to hOAT2 expression in human liver.Clin Chim Acta2010;411:99-105

[107] Cropp CD,Shima JE.Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP.Mol Pharmacol2008;73:1151-8 PMCID:PMC2698938

[108] Valdés R,Pastor-Anglada M.Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs.Biochem Biophys Res Commun2002;296:575-9

[109] Ritzel MW,Ng AM,Cass CE.Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine.Mol Membr Biol1998;15:203-11

[110] Errasti-Murugarren E,Casado FJ.Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs.J Physiol2007;582:1249-60 PMCID:PMC2075247

[111] Kong W,Wang J.Mammalian nucleoside transporters.Curr Drug Metab2004;5:63-84

[112] Pennycooke M,Shuralyova I,Coe IR.Differential expression of human nucleoside transporters in normal and tumor tissue.Biochem Biophys Res Commun2001;280:951-9

[113] Garcia-Manteiga J,Casado FJ,Pastor-Anglada M.Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2’,2’-difluorodeoxycytidine- induced cytotoxicity.Clin Cancer Res2003;9:5000-8

[114] Graham KA,Coe IR.Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.Nucleosides Nucleotides Nucleic Acids2000;19:415-34

[115] Jaramillo AC,Broekhuizen R.Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia.Nucleosides Nucleotides Nucleic Acids2020;39:1379-88

[116] Niitani M,Okuda H,Fujimoto S.Transport characteristics of mouse concentrative nucleoside transporter 1.Int J Pharm2010;388:168-74

[117] Gray JH,Giacomini KM.The concentrative nucleoside transporter family, SLC28.Pflugers Arch2004;447:728-34

[118] Johnson SA.Nucleoside analogues in the treatment of haematological malignancies.Expert Opin Pharmacother2001;2:929-43

[119] Bhutia YD,Patel B,Govindarajan R.CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.Cancer Res2011;71:1825-35 PMCID:PMC3048166

[120] Soo RA,Ng SS.Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.Lung Cancer2009;63:121-7

[121] Innocenti F,Sibley AB.An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).Pharmacogenet Genomics2019;29:123-31 PMCID:PMC6636684

[122] Khatri A,Fisher J.SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Br J Cancer2014;110:304-12 PMCID:PMC3899768

[123] Suenaga M,Cao S.Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.Eur J Cancer2017;86:197-206 PMCID:PMC7497848

[124] Tanaka M,Dong X,Abbruzzese JL.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Cancer2010;116:5325-35 PMCID:PMC2966859

[125] Lee SY,Park YH.Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.Eur J Cancer2014;50:698-705

[126] Limviphuvadh V,Konishi F.Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.BMC Cancer2018;18:555 PMCID:PMC5948914

[127] Elsayed AH,Crews KR.Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.Pharmacogenomics2018;19:1101-10 PMCID:PMC6219441

[128] Mitra AK,Khatri A.Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.Pharmacogenomics2012;13:1009-21

[129] Shin HC,Sun D.Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum.Biochem Biophys Res Commun2003;307:696-703

[130] Yee SW,Hesselson S.Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2).J Pharmacol Exp Ther2009;328:699-707 PMCID:PMC2682268

[131] Ritzel MWL,Yao SYM.Molecular identification and characterization of novel human and mouse concentrative Na⁺-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib).J Biol Chem2001;276:2914-27

[132] Song JH,Kim HJ.Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy.Oncol Rep2015;34:488-94

[133] Fotoohi AK,Peterson C.Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines.Biochem Biophys Res Commun2006;343:208-15

[134] Matimba A,Livshits A.Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Pharmacogenomics2014;15:433-47 PMCID:PMC4027966

[135] Jo JK,Kim YT.A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.Oncotarget2017;8:96893-902 PMCID:PMC5722531

[136] Clarke ML,Baldwin SA,Cass CE.The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.Cancer Treat Res2002;112;27-47

[137] Reese ND.High-dose cytarabine (HD araC) in the treatment of leukemias: a review.Curr Hematol Malig Rep2013;8:141-8

[138] Kim KI,Kim IW.Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.Eur J Cancer2013;49:403-10

[139] Amaki J,Ohmachi K.Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.Int J Hematol2015;101:543-53

[140] Wan H,Chen F.SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.J Exp Clin Cancer Res2014;33:90 PMCID:PMC4234887

[141] Magos A,Turnbull AC.Management of ruptured and unruptured ectopic pregnancies by videopelviscopy.Lancet1988;2:275-6

[142] Petris MJ.The SLC31 (Ctr) copper transporter family.Pflugers Arch2004;447:752-5

[143] Ishida S,Thiele DJ.Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.Proc Natl Acad Sci U S A2002;99:14298-302 PMCID:PMC137878

[144] Holzer AK,Howell SB.Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.Mol Pharmacol2006;70:1390-4

[145] Dasari S.Cisplatin in cancer therapy: molecular mechanisms of action.Eur J Pharmacol2014;740:364-78 PMCID:PMC4146684

[146] Whirl-Carrillo M,Hebert JM.Pharmacogenomics knowledge for personalized medicine.Clin Pharmacol Ther2012;92:414-7 PMCID:PMC3660037

[147] Tate JG,Jubb HC.COSMIC: the catalogue of somatic mutations in cancer.Nucleic Acids Res2019;47:D941-7 PMCID:PMC6323903

[148] Xu X,Zhou B,Zhou H.Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.Clin Exp Pharmacol Physiol2012;39:786-92

[149] Sun C,Qie J.Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation.Oncotarget2018;9:23860-77 PMCID:PMC5963629

[150] Xu X,Zhou B.Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.Lung Cancer2012;77:438-42

[151] Drögemöller BI,Bhavsar AP.Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer.JAMA Oncol2017;3:1558-62 PMCID:PMC5824214

[152] Giglia JL,Hart AJ.A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.Biol Blood Marrow Transplant2014;20:1014-20 PMCID:PMC4076151

[153] Candelaria M,Gutierrez-Hernandez O,Vidal-Millan S.G80A single nucleotide polymorphism in reduced folate carrier-1 gene in a mexican population and its impact on survival in patients with acute lymphoblastic leukemia.Rev Invest Clin2016;68:154-62

[154] Jabeen S,Alnæs GI,Hall KS.Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.Pharmacogenomics J2015;15:385-90

[155] Suthandiram S,Zain SM.Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.Pharmacogenomics2014;15:1479-94

[156] Park JA.Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma.Blood Res2016;51:50-7 PMCID:PMC4828529

[157] Pongmaneratanakul S,Pengsuparp T.Prevalence of CTR1 and ERCC1 polymorphisms and response of biliary tract cancer to gemcitabine-platinum chemotherapy.Asian Pac J Cancer Prev2017;18:857-61 PMCID:PMC5464510

[158] Otsuka M,Morimoto R,Omote H.A human transporter protein that mediates the final excretion step for toxic organic cations.Proc Natl Acad Sci U S A2005;102:17923-8 PMCID:PMC1312386

[159] Tanihara Y,Sato T,Ogawa O.Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H⁺-organic cation antiporters.Biochem Pharmacol2007;74:359-71

[160] Terada T.Physiological and pharmacokinetic roles of H⁺/organic cation antiporters (MATE/SLC47A).Biochem Pharmacol2008;75:1689-96

[161] Masuda S,Yonezawa A.Identification and functional characterization of a new human kidney-specific H⁺/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.J Am Soc Nephrol2006;17:2127-35

[162] Yonezawa A,Yokoo S,Inui K.Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).J Pharmacol Exp Ther2006;319:879-86

[163] Yokoo S,Masuda S,Katsura T.Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.Biochem Pharmacol2007;74:477-87

[164] Nies AT,Leuthold P.Novel drug transporter substrates identification: An innovative approach based on metabolomic profiling, in silico ligand screening and biological validation.Pharmacol Res2023;196:106941

[165] Kajiwara M,Ogasawara K.Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.J Hum Genet2009;54:40-6

[166] Teft WA,Nichols AC.Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients.Oral Oncol2019;89:72-8

[167] Navale AM.Glucose transporters: physiological and pathological roles.Biophys Rev2016;8:5-9 PMCID:PMC5425736

[168] Pliszka M.Glucose transporters as a target for anticancer therapy.Cancers2021;13:4184 PMCID:PMC8394807

[169] Mano Y,Kubo Y.Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma.Am J Clin Pathol2014;142:391-7

[170] Yu M,Chen S.The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis.Oncotarget2017;8:43356-67 PMCID:PMC5522151

[171] Reinicke K,Cisterna P,Nualart F.Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.J Cell Biochem2012;113:553-62

[172] Huang XQ,Xie XX.Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma.Int J Clin Exp Pathol2014;7:1651-66 PMCID:PMC4014246

[173] Sobanski T,Suraweera A,Richard DJ.Cell metabolism and DNA repair pathways: implications for cancer therapy.Front Cell Dev Biol2021;9:633305 PMCID:PMC8021863

[174] Chen J,Wang Y.Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity.Tumour Biol2016;37:2275-84

[175] Kim YH,Pak K.SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma.Oncotarget2017;8:68381-92 PMCID:PMC5620264

[176] Daskalow K,Weichert W.Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma.Histochem Cell Biol2009;132:21-31

[177] Godoy A,Rodríguez F.Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.J Cell Physiol2006;207:614-27

[178] Kanai Y,Miyamoto Ki,Takeda E.Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98).J Biol Chem1998;273:23629-32

[179] Yanagida O,Chairoungdua A.Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines.Biochim Biophys Acta2001;1514:291-302

[180] Zhang J,Li D.Review of the correlation of LAT1 with diseases: mechanism and treatment.Front Chem2020;8:564809 PMCID:PMC7606929

[181] Maimaiti M,Yamada Y.Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.Sci Rep2020;10:1292 PMCID:PMC6987139

[182] Yanagisawa N,Mikami T.High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.J Clin Pathol2012;65:1019-23

[183] Lin J,Thomas DG.L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma.Neoplasia2004;6:74-84 PMCID:PMC1508631

[184] Greig NH,Rapoport SI.Melphalan concentration dependent plasma protein binding in healthy humans and rats.Eur J Clin Pharmacol1987;32:179-85

[185] Geier EG,Fan H.Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1.Proc Natl Acad Sci U S A2013;110:5480-5 PMCID:PMC3619328

[186] Sekine M,Nakamoto K.Selective inhibition of L-type amino acid transporter 1 suppresses cell proliferation in ovarian clear cell carcinoma.Anticancer Res2023;43:2509-17

[187] Shi Z,Ohgaki R.Inhibition of cancer-type amino acid transporter LAT1 suppresses B16-F10 melanoma metastasis in mouse models.Sci Rep2023;13:13943 PMCID:PMC10457391

[188] Nishikubo K,Liu X.Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells.Cancer Cell Int2023;23:116 PMCID:PMC10268460

[189] Sierra EE,Spinella MJ.pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH.Biochem Pharmacol1997;53:223-31

[190] Puris E,Gynther M.The role of solute carrier transporters in efficient anticancer drug delivery and therapy.Pharmaceutics2023;15:364 PMCID:PMC9966068

[191] Qiu A,Sakaris A.Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.Cell2006;127:917-28

[192] Alam C,Finnell RH,Bendayan R.Regulation of reduced folate carrier (RFC) by vitamin D receptor at the blood-brain barrier.Mol Pharm2017;14:3848-58 PMCID:PMC6952265

[193] Westerhof GR,Kathmann I.Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.Mol Pharmacol1995;48:459-71

[194] Desmoulin SK,Wu J.Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.Mol Pharmacol2010;78:577-87 PMCID:PMC2981399

[195] Matherly LH,Deng Y.Human reduced folate carrier: translation of basic biology to cancer etiology and therapy.Cancer Metastasis Rev2007;26:111-28

[196] Lima A,Azevedo R.SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.Toxicol Sci2014;142:196-209

[197] Hou Z.Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.Curr Top Membr2014:73:175-204 PMCID:PMC4185403

[198] Lau DT,Gherardi S.MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.Oncotarget2015;6:15510-23 PMCID:PMC4558167

[199] Odin E,Gustavsson B,Wettergren Y.Expression of folate pathway genes in stage III colorectal cancer correlates with recurrence status following adjuvant bolus 5-FU-based chemotherapy.Mol Med2015;21:597-604 PMCID:PMC4656203

[200] Nunez MI,Woods DM.High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.J Thorac Oncol2012;7:833-40 PMCID:PMC3383601

[201] Gonen N.Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.Drug Resist Updat2012;15:183-210

[202] Desmoulin SK,Gangjee A.The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Cancer Biol Ther2012;13:1355-73 PMCID:PMC3542225

[203] Visentin M,Goldman ID.The antifolates.Hematol Oncol Clin North Am2012;26:629-48 PMCID:PMC3777421

[204] Zhang X,Huang L.Discovery of novel biomarkers of therapeutic responses in han chinese pemetrexed-based treated advanced NSCLC patients.Front Pharmacol2019;10:944 PMCID:PMC6716463

[205] Salazar J,del Río E.Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.Pharmacogenomics J2012;12:379-85

[206] Laverdière I,Tamouza R.Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.Haematologica2015;100:275-83 PMCID:PMC4803136